Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer

April 3rd 2018

The European Medicines Agency has accepted a marketing authorization application for olaparib to treat women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

Dr. Durand Discusses Treatment Options for Toxicities from Therapy in HER2+ Breast Cancer

April 2nd 2018

Jean-Bernard Durand, MD, professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center, discusses advice for community oncologists on managing patients that are experiencing symptoms from treatment for HER2-positive breast cancer.

AKT Inhibitor May Overcome Chemotherapy Resistance in 2 Breast Cancer Subtypes

April 2nd 2018

A novel inhibitor that targets the AKT node in the PI3K pathway may offer a treatment option in cases of resistance to chemotherapy in 2 patient populations: triple-negative breast cancer or ER-positive/HER2-negative breast cancer with certain molecular aberrations.

Dr. Pegram on Developing Agents for Patients With HER2+ Breast Cancer and Brain Metastases

April 2nd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

Dr. Khong on the Benefit of Neoadjuvant Endocrine Therapy in ER+ Breast Cancers

March 30th 2018

Hung T. Khong, MD, medical oncologist, Moffitt Cancer Center, discusses the use of neoadjuvant endocrine therapy.

Dr. Han on the Differences Between CDK 4/6 Inhibitors in ER+ Breast Cancer

March 30th 2018

Heather S. Han, MD, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discusses the differences between CDK 4/6 inhibitors, and their efficacy as both single- and combination agents.

Final Insight: PARPs and gBRCA in Breast Cancer

March 30th 2018

Testing for Germline BRCA Mutations in the Future

March 30th 2018

PARP Inhibitors in Other Subtypes of Breast Cancer

March 30th 2018

Distinguishing Between PARP Inhibitors in Breast Cancer

March 30th 2018

PARP Inhibitors and Platinum Sensitivity or Resistance

March 30th 2018

Additional PARPs Under Investigation for Breast Cancer

March 30th 2018

Using Olaparib in gBRCA1/2+ Breast Cancer

March 30th 2018

Olaparib: Predicting Response in Breast Cancer

March 30th 2018

Takeaways From the OlympiAD Trial

March 30th 2018

Chemotherapy in Early-Stage gBRCA1/2+ Breast Cancer

March 30th 2018

Chemotherapy in gBRCA1/2+ Metastatic Breast Cancer

March 30th 2018

Germline BRCA1/2: A New Subset of Breast Cancer

March 30th 2018

Implications for Germline BRCA Testing in Breast Cancer

March 30th 2018

Emerging Options for BRCA-Mutated Breast Cancer Treatment

March 30th 2018